Results 291 to 300 of about 101,548 (353)

Shortages of benzathine benzylpenicillin G in Australia highlight the need for new sovereign manufacturing capability

Medical Journal of Australia, Volume 222, Issue 5, Page 223-225, March 2025.
Rosemary Wyber, Glenn Pearson, Laurens Manning   +2 more
wiley   +1 more source

Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes.

JAMA Netw Open
Li JX, Hsu TJ, Lin HJ, Hsu SB, Lu CR, Chung WH, Liang SJ, Tsai FJ, Chang KC.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

Science Translational Medicine, 2018
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach. Assisting absorption Glucagon-like peptide-1 receptor agonists can help treat type 2 diabetes but must be ...
S. Buckley, T. Bækdal, A. Vegge, S. Maarbjerg, C. Pyke, J. Ahnfelt-Rønne, Kim G Madsen, Susanne G Schéele, T. Alanentalo, R. K. Kirk, B. Pedersen, R. B. Skyggebjerg, A. J. Benie, H. Strauss, Per-Olof Wahlund, S. Bjerregaard, E. Farkas, C. Fekete, F. Søndergaard, Jeanett Borregaard, M. Hartoft‐Nielsen, L. Knudsen   +21 more
semanticscholar   +1 more source

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist

Diabetes Technology & Therapeutics, 2020
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have ...
John D. Bucheit, Lauren G. Pamulapati, Nicole Carter, K. Malloy, Dave L Dixon, E. Sisson   +5 more
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists

Incretin hormones are glucoregulatory neurohormones, and GLP-1 and GIP account for about 90% of the incretin effect.1 GLP-1 and GIP are secreted in response to food ingestion and act on the pancreas to stimulate glucose-dependent insulin secretion and blunt inappropriate glucagon secretion ...
Heather P. Whitley, Jennifer M. Trujillo
  +4 more sources

Renal protection with glucagon-like peptide-1 receptor agonists

Current Opinion in Pharmacology, 2020
There is an unmet need for renoprotective drugs for more pronounced reduction of albuminuria beyond that provided by renin-angiotensin system (RAS) blockers and for effective slowdown of eGFR decline independent of albuminuria. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have proven effective in reducing prespecified secondary composite ...
Vitale M., Haxhi J., Cirrito T., Pugliese G.   +3 more
openaire   +2 more sources